ALK and non-small cell lung carcinoma: Meta-analyses of single-arm clinical trials with different doses of ALK inhibitors, such as alectinib, ceritinib, brigatinib, and crizotinib, have shown that the combined objective response rates for ALK-p NSCLC with CNS metastases were 79%, 45%, 48%, and 18%, respectively [49].